Background: Lung cancer is the most frequent cause of cancer-related deaths worldwide. The clinical development of immune checkpoint blockade has dramatically changed the treatment paradigm for patients with lung cancer. Yet, an improved understanding of PD-1/PD-L1 checkpoint blockade-responsive biology is warranted. Methods: We aimed to identify the landscape of immune cell infiltration in primary lung adenocarcinoma (LUAD) in the context of tumoral PD-L1 expression and the extent of immune infiltration (“hot” vs. “cold” phenotype). The study comprises LUAD cases (n = 138) with “hot” (≥150 lymphocytes/HPF) and “cold” (50%) and negative (<1%) tumor PD-L1 expression, respectively. Tumor samples were immunohistochemically analyzed for express...
Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung c...
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with ...
Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung c...
Background: Lung cancer is the most frequent cause of cancer-related deaths worldwide. The clinical ...
Gene amplification is considered to be one responsible cause for upregulation of Programmed Death Li...
BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both...
Background In non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or bot...
Background Programmed cell death ligand 1 (PD-L1) expressed on tumor and immune cells are both assoc...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression ...
Background: Programmed cell death-ligand 1 (PD-L1) is expressed in a subgroup of lung cancer that ma...
Background: Predictive biomarkers for immunotherapy in lung cancer are intensively investigated; how...
Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung c...
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with ...
Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung c...
Background: Lung cancer is the most frequent cause of cancer-related deaths worldwide. The clinical ...
Gene amplification is considered to be one responsible cause for upregulation of Programmed Death Li...
BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both...
Background In non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or bot...
Background Programmed cell death ligand 1 (PD-L1) expressed on tumor and immune cells are both assoc...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression ...
Background: Programmed cell death-ligand 1 (PD-L1) is expressed in a subgroup of lung cancer that ma...
Background: Predictive biomarkers for immunotherapy in lung cancer are intensively investigated; how...
Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung c...
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with ...
Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung c...